Susquehanna International Group
TRIL

Susquehanna International Group’s Trillium Therapeutics Inc. TRIL Stock Holding History

Susquehanna International Group’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q4 		– Sell
-298,500
Closed -$5.24M – 14455
2021
Q3 		$5.24M Buy
298,500
+186,900
+167% +$2.18M ﹤0.01% 3863
2021
Q2 		$1.08M Buy
111,600
+6,300
+6% +$59.3K ﹤0.01% 7548
2021
Q1 		$1.13M Sell
105,300
-33,300
-24% -$412K ﹤0.01% 7404
2020
Q4 		$2.04M Buy
138,600
+61,100
+79% +$881K ﹤0.01% 5054
2020
Q3 		$1.1M Buy
77,500
+29,200
+60% +$291K ﹤0.01% 5869
2020
Q2 		$391K Buy
48,300
+8,100
+20% +$50.1K ﹤0.01% 7866
2020
Q1 		$162K Buy
+40,200
New +$152K ﹤0.01% 8921
2018
Q2 		– Sell
-16,800
Closed -$121K – 10729
2018
Q1 		$121K Sell
16,800
-17,800
-51% -$135K ﹤0.01% 8629
2017
Q4 		$251K Buy
+34,600
New +$287K ﹤0.01% 7882

Other funds holding TRIL

Optiver Holding
Optiver Holding Amsterdam, Netherlands $289B AUM 33.63% 1-Year Est. Return

Susquehanna International Group's TRIL Position: Q4 2021 in Review

Susquehanna International Group sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2021, closing a stake of 379,627 shares — an estimated $6.67M sold.

Susquehanna International Group first reported a position in TRIL in Q3 2016 and held it in 9 quarters. The position peaked at $6.67M in Q3 2021. 2 funds tracked by Wall St. Rank hold TRIL as of Q4 2021.

  • Susquehanna International Group reported no remaining Trillium Therapeutics Inc. position as of Q4 2021 after selling out during the quarter.
  • Susquehanna International Group sold 379,627 Trillium Therapeutics Inc. shares in Q4 2021, an estimated $6.67M.
  • Susquehanna International Group first reported a position in Trillium Therapeutics Inc. in Q3 2016 and held it in 9 quarters.
  • Susquehanna International Group's Trillium Therapeutics Inc. position peaked at $6.67M in Q3 2021.
  • 2 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2021.

Based on Susquehanna International Group's 13F filing for Q4 2021, filed 14 Feb 2022.